|
Alexion Pharmaceuticals was hit with a warning letter from the U.S. Food and Drug Administration over its investigation of bacterial contamination at its Rhode Island facility, reported MarketWatch’s Health Exchange blog.
more
By PBN Staff
|
|
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology, and launched the biotechnology industry’s first blockbuster medicines.
more
By Richard Asinof
Contributing Writer | 6/25/12 |
|
Age: 33
more
7/23/12
|
|
Age: 36
more
7/23/12
|
|
IlluminOss Medical Inc. has named Dirk M. Kuyper its new president and CEO effective Monday. Kuyper is taking over for Scott Rader, whose position with the company ended in late October, the company announced Tuesday.
more
By PBN Staff
|
|
PROVIDENCE – Performance Physical Therapy recently announced the opening of its newest of six clinics, in the Smithfield Medical Center in Smithfield. A seventh clinic is scheduled to open later this month in Barrington at 310 Maple Ave.
more
8/20/12
|
|
Connectivity, collaboration and opportunity: These are the watchwords of industry leaders from the Rhode Island medical-technology community who are organizing a new statewide cluster.
more
By Richard Asinof
Contributing Writer | 2/4/13 |
|
The 2013 edition of the Rhode Island Business Plan Competition announced its winners Tuesday afternoon at The Garage, the Greater Providence Chamber of Commerce’s exposition dedicated to identifying and inspiring high-growth companies in the Ocean State.
more
By PBN Staff
|
|
WOONSOCKET – MultiCell Technologies announced on Aug. 10 its updates on preclinical research results for MCT-465 and MCT-485, the first of a family of prospective cancer therapeutics based on the use of its patented signaling technology. MCT-465 and MCT-485 are being investigated as prospective treatments for primary liver cancer and triple-negative breast cancer.
more
8/20/12
|
|
Amgen Inc., which has a production facility in West Greenwich, reported first-quarter profit that beat analyst estimates because of a research tax credit.
more
By Ryan Flinn |
